Business Finance General News Technology Top Stories

Epidermal Growth Factor Receptor (EGFR) Antagonists Therapeutics – Pipeline Analysis 2019, Clinical Trials & Results

Press Release

Epidermal growth factor receptors (EGFR) are a group of receptor tyrosine kinase (RTK) that plays a major role in cell proliferation, survival and differentiation. In most of the cancer, EGFR are amplified and overexpressed, due to dysregulation, resulting in cancer development.

EGFR inhibitors therapies have shown improvement by inhibiting receptor signalling and enhancing the effects of radiation therapy and conventional chemotherapy with their anti-tumor activity. Cetuximab, Panitumumab, Erlotinib and Afatinib are some of the major marketed drugs as anti-EGFR therapies for the treatment of colorectal cancer, head and neck cancer and non-small cell lung cancer.

Access Detailed Report Summary:

Daiichi Sankyo Co., Ltd. is in the process of developing Nimotuzumab as a humanized monoclonal antibody which acts as an EGFR inhibitor for the treatment of gastric cancer. Some of the other companies having pipeline of EGFR inhibitors include Daiichi Sankyo Co., Ltd., Shionogi & Co. Ltd., AstraZeneca PLC, and Amgen Inc.

Request to Get the Sample Pages at:

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Read More…

About P&S Intelligence

P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.


P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)

International: +1-347-960-6455

Email: [email protected]


Connect with us: LinkedIn | Twitter | Facebook

This post was originally published on Raleigh Recorder

RSS news